HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Executive Decisions Roundup

This article was originally published in The Tan Sheet

Executive Summary

Another Coca-Cola exec pops up at NBTY; Hussain helms Glaxo pharma globally; China TCM office veteran returns; T-Bird tabs Huang as COO; and Lee named Calif. DTSC director.

You may also be interested in...



Carlyle Group Gives NBTY Helm To Former Coca-Cola Executive Cahillane

Steven Cahillane, who left his post as president of Coca-Cola Co.’s Americas division in 2013, is moving to NBTY to replace Jeffrey Nagel after the supplement manufacturer and retailer reported flat sales for its most recent earnings period and after net income dropped nearly 12% during the firm’s previous fiscal year.

US FDA Portal Open To Receive OTC Monograph Meeting Requests

Submitting other OTC monograph program communications through CDER's NextGen Portal, including proposals to add formulations or indications to a monograph, will have to wait.

SCARs Label Warning For OTC PPIs In US Starts With Perrigo’s 131 Omeprazole Product Options

FDA approves warning for severe cutaneous adverse reactions on labeling for Perrigo's 131 20-mg omeprazole delayed-release tablet products across unflavored and cool mint or wild berry-mint options and 14-, 28- and 42-count packages. 

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS139628

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel